Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).

Lenvatinib is often used in both first- and second-line settings, Cabanillas explains. 

In clinical practice, Cabanillas often uses lenvatinib versus sorafenib in patients with aggressive disease that is rapidly progressing. However, both lenvatinib and sorafenib can be used as first-line treatments, she adds. 

View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC